Newsletter Signup x
Diffuse Midline Gliomas (DMGs) are a major subtype of Paediatric-Type Diffuse High-Grade Glioma that localise to the brainstem.
Investigating Treatment Resistance in Paediatric-Type Diffuse High-Grade Glioma
Dr Manavendra Pathania
University of Cambridge
Cambridge, CB2 0XZ
1 October 2025
36 months
£348,662
Diffuse Midline Gliomas (DMGs) are a major subtype of Paediatric-Type Diffuse High-Grade Glioma that localise to the brainstem. The goal of this proposal is to try to understand how DMGs so rapidly adapt and develop resistance to radiotherapy and chemotherapy.
This work will reveal new mechanisms of resistance in DMGs, which could be targeted to make current treatments more effective.
Manav Pathania is an expert in developing immunocompetent mouse models of DMG. Claudia Kleinman is an expert in single-cell RNA sequencing, which will be used to identify the gene expression programmes of individual cells in naïve and resistant tumours. Nada Jabado is a clinician and a world renowned expert in DMG biology who has also curated data and human tissue collections, which we will use to cross-reference our findings in mouse models to make sure they are clinically relevant. Finally, Greg Hannon is a world renowned expert in developing tools to interrogate cancer biology. His lab has developed the lentiviral barcode library that we will use to track the gene expression programmes of single cells in naive vs resistant tumours.
Patient Story – Gaspard
Gaspard was diagnosed with rhabdomyosarcoma in 2018 when he was three. His mum Caroline tells their
Read more
Patient Story – Chester
Chester was diagnosed with acute lymphoblastic leukaemia on 16 March 2024 when he was just four years old. His
Read more